Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:00am, Monday, 04'th May 2026
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
FDA Reports Liver Failure in Patient Taking Lilly's Foundayo
09:48am, Monday, 04'th May 2026
The Food and Drug Administration has recorded two ‘serious' cases in patients taking Eli Lilly's weight-loss pill.
This Pharma Stock Keeps Earning My Money, Here's Why
09:15am, Monday, 04'th May 2026
I keep buying Eli Lilly (NYSE:LLY | LLY Price Prediction), and the latest quarter just made it harder to stop.
Why Eli Lilly Stock Jumped This Week
08:48pm, Sunday, 03'rd May 2026
Mounjaro and Zepbound are driving Eli Lilly's earnings sharply higher. Foundayo looks like another top-seller.
Weekend Morning Brew: Big Tech AI Capex Surges as Oil Spikes
07:36am, Saturday, 02'nd May 2026
Weekly Market HighlightsWeekly breadth was moderately positive with 4,963 advancers versus 4,504 decliners, including 918 stocks up more than 10% and 855 stock
Eli Lilly: Buying Opportunity Knocking On The Front Door Again (Rating Upgrade)
08:31am, Friday, 01'st May 2026
Eli Lilly (LLY) outperformed with robust Q1 results showing 56% revenue growth and an EPS of $8.55, calming the market's nerves and anxiety. LLY's market share gains in incretin analogs have plateaued
Eli Lilly and Co (LLY) Stock Up 9.8% and Still Undervalued -- GF Score: 95/100
05:02pm, Thursday, 30'th Apr 2026
On April 30, 2026, Eli Lilly and Co (LLY) shares rose 9.8% to a current price of $934.60. This price movement occurred within a 52-week range of $623.78 to $113
Eli Lilly and Company (LLY) Q1 2026 Earnings Call Transcript
03:11pm, Thursday, 30'th Apr 2026
Eli Lilly and Company (LLY) Q1 2026 Earnings Call Transcript
LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised
02:05pm, Thursday, 30'th Apr 2026
LLY jumps after crushing Q1 estimates and raising 2026 outlook, powered by surging Mounjaro and Zepbound sales and strong global demand.
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand
12:03pm, Thursday, 30'th Apr 2026
Eli Lilly and Co. (NYSE:LLY) stock is trading higher after the weight loss drug giant released better-than-expected first quarter 2026 earnings and raised fiscal 2026 guidance.
Demand for Weight-Loss Drugs Drove Blockbuster Results for Eli Lilly. Its Stock Is Surging.
11:16am, Thursday, 30'th Apr 2026
Eli Lilly's stock is powering higher on fresh signs of booming demand for its weight-loss drugs. Will it be enough to drive a recovery for the stock?
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
11:02am, Thursday, 30'th Apr 2026
The Food and Drug Administration proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's blockbuster obesity and diabetes medications from the list of drugs that ou
Compared to Estimates, Lilly (LLY) Q1 Earnings: A Look at Key Metrics
10:35am, Thursday, 30'th Apr 2026
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates a
QCOM Rally, RCL Regains Bookings Pace, LLY Soars
10:24am, Thursday, 30'th Apr 2026
While Mag 7 names take a lot of the headlines after earnings, the moves from Qualcomm (QCOM), Royal Caribbean (RCL) and Eli Lilly (LLY) are on Diane King Hall's radar following Thursday's open. She br
US FDA proposes excluding weight-loss drugs from compounding list
09:54am, Thursday, 30'th Apr 2026
The U.S. Food and Drug Administration on Thursday proposed excluding active ingredients for Novo Nordisk and Eli Lilly's weight-loss drugs on the list of drugs outsourcing facilities can use
